Tuesday 17 November 2026Search
World

FDA launches Global Reliance Disclosure Program for medicines worldwide

1 min read

The Food and Drug Administration announced the launch of the Global Reliance Disclosure Program. The program launched on Oct. 30 with a PEPFAR tentative approval for lenacapavir, a drug indicated for HIV prevention and treatment.

Under the program, the FDA shares minimally redacted approval packages, including its scientific and regulatory assessments, directly with companies. Companies can provide the packages to regulatory authorities outside the United States for their marketing applications.

The FDA said the program allows foreign regulatory authorities to rely on its approval decisions instead of conducting duplicative product evaluations. The authorities retain responsibility for their regulatory decisions.

The program is currently available to PEPFAR tentative approvals. It excludes tentatively approved abbreviated new drug application products. The FDA said it intends to expand the program in January 2027 to all novel drugs and biologics.

The FDA also intends to launch a pathway in early 2027 for applicants to request minimally redacted action packages for approved and licensed drugs and biologics. It said the pathway would support access to medicines already marketed in the United States that the FDA found safe and effective.

Applicants must request participation within 10 calendar days of approval. They must also confirm that the application package is being submitted to a foreign regulatory authority to support a marketing application. The FDA said eligible applicants would receive detailed information in approval letters and receive the packages on an expedited basis. Requests for other purposes will be handled through the Freedom of Information Act.